Eam Investors, LLC Axsome Therapeutics, Inc. Transaction History

Eam Investors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$58.41 - $90.35 $1.06 Million - $1.64 Million	18,102 New	18,102 $1.3 Million
Q4 2022 Feb 14, 2023	SELL	$39.94 - $79.72 $1.5 Million - $3 Million	-37,634 Reduced 72.25%	14,458 $1.12 Million
Q3 2022 Nov 14, 2022	BUY	$36.06 - $69.85 $33,607 - $65,100	932 Added 1.82%	52,092 $2.32 Million
Q2 2022 Aug 12, 2022	BUY	$21.74 - $46.75 $1.11 Million - $2.39 Million	51,160 New	51,160 $1.96 Million
Q3 2020 Nov 13, 2020	SELL	$68.34 - $85.84 $2 Million - $2.51 Million	-29,293 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$49.87 - $98.69 $2.29 Million - $4.53 Million	-45,942 Reduced 61.06%	29,293 $2.41 Million
Q1 2020 May 13, 2020	BUY	$41.2 - $101.31 $151,574 - $372,719	3,679 Added 5.14%	75,235 $4.43 Million
Q4 2019 Feb 11, 2020	SELL	$16.71 - $106.24 $969,647 - $6.16 Million	-58,028 Reduced 44.78%	71,556 $7.4 Million
Q3 2019 Nov 13, 2019	SELL	$20.24 - $29.16 $382,272 - $550,744	-18,887 Reduced 12.72%	129,584 $2.62 Million
Q2 2019 Aug 14, 2019	SELL	$13.46 - $25.75 $1.06 Million - $2.03 Million	-78,770 Reduced 34.66%	148,471 $3.82 Million
Q1 2019 May 13, 2019	BUY	$2.63 - $16.34 $597,643 - $3.71 Million	227,241 New	227,241 $3.23 Million

325

37.7M

912K

855K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.89B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.